Download PDF
Z Gastroenterol 2004; 42(8): 767-773
DOI: 10.1055/s-2004-813342
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Diagnostik, Staging und Therapie des Magenkarzinoms

Diagnosis, Staging and Therapy of Gastric CancerM. Menges1
  • 1Klinik für Innere Medizin, Diakonie-Krankenhaus, Schwäbisch Hall
Further Information

Publication History

Publication Date:
16 August 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Während die Inzidenz des Magenkarzinoms im Westen kontinuierlich sinkt, stellt es weltweit nach wie vor eine der häufigsten tumorbedingten Todesursachen dar. Für die große Mehrheit der sporadischen Tumoren ist die molekulare Pathogenese weiterhin im Detail ungeklärt, für einzelne familiäre Karzinomformen konnten ursächliche Keimbahnmutationen detektiert werden. Nur die onkologisch radikale Resektion bietet Aussicht auf Heilung, dabei wird die Prognose vom Tumorstadium bestimmt - leider befinden sich im Westen noch immer etwa zwei Drittel der Patienten in einem fortgeschrittenen Stadium bei Diagnose.

Die Ergebnisse der chirurgischen Therapie sind auf einem Plateau angelangt, im Stadium IIIB und IV (UICC) gelingt nur in etwa 40 % eine prognostisch entscheidende R0-Resektion, und auch bei erfolgter kurativer Resektion ist die Rezidivrate - stadienabhängig - sehr hoch. Der Nutzen einer neoadjuvanten Chemotherapie bei lokal irresektablen Tumoren konnte in Phase-II-Studien hinreichend belegt werden. Weniger klar ist das Vorgehen in der adjuvanten Situation: Hier gilt es, den Nutzen einer Radiochemotherapie auch unter erfolgter systematischer Lymphadenektomie zu beweisen. In der palliativen Situation gelten derzeit platinbasierte 5-FU-Hochdosisprotokolle als Standard, dem sich moderne Substanzen wie Taxane oder Irinotecan bislang nicht als überlegen erwiesen haben.

Abstract

In spite of a continuously decreasing incidence in Western countries, gastric cancer remains a major health problem world-wide and a leading cause of cancer-related deaths. The molecular pathogenesis of the vast majority of sporadic tumours has not yet been clarified in detail, while for some familial cancer types causal germline mutations have been identified. Only radical resection offers a chance of cure and the prognosis is determined by the stage of disease at diagnosis. Unfortunately, about two-thirds of patients are still diagnosed in a late stage. The results of surgery have reached a plateau of effectiveness, in stages III and IV (UICC) an R0 resection will be possible in only about 40 % of cases and even, after successful curative resection, the prognosis is limited due to a high recurrence rate. The benefit of neoadjuvant chemotherapy in locally advanced cancers has been verified in phase II studies. Less clear is the adjuvant situation - the benefit of adjuvant radiochemotherapy after systematic lymphadenectomy awaits to be proven. In the palliative situation platinum-based high-dose 5-FU infusion protocols are currently the standard therapy.

Schlüsselwörter

Magenkarzinom - Diagnostik - Staging - Therapie - adjuvant - neoadjuvant - palliativ - Übersicht

Key words

Gastric cancer - diagnosis - staging - therapy - adjuvant - neoadjuvant - palliative - review

Literatur

  • 1 Boring C C, Squires T S, Tong T. et al . Cancer statistics, 1994.  CA Cancer J Clin. 1994;  44 7-26
    PubMedGoogle Scholar
  • 2 Guiraldes E, Pena A, Duarte I. et al . Nature and extent of gastric lesions in symptomatic Chilean children with Helicobacter pylori-associated gastritis.  Acta Paediatr. 2002;  91 39-44
    CrossrefPubMedGoogle Scholar
  • 3 Richards F M, McKee S A, Rajpar M H. et al . Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer.  Hum Mol Genet. 1999;  8 607-610
    CrossrefPubMedGoogle Scholar
  • 4 Becker K F, Keller G, Hoefler H. The use of molecular biology in diagnosis and prognosis of gastric cancer.  Surg Oncol. 2000;  9 5-11
    CrossrefPubMedGoogle Scholar
  • 5 Stadtlander C T, Waterbor J W. Molecular epidemiology, pathogenesis and prevention of gastric cancer.  Carcinogenesis. 1999;  20 2195-2208
    CrossrefPubMedGoogle Scholar
  • 6 Graham D Y, Schwartz J T, Cain G D. et al . Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.  Gastroenterology. 1982;  82 228-231
    PubMedGoogle Scholar
  • 7 Kelly S, Harris K M, Berry E. et al . A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma.  Gut. 2001;  49 534-539
    CrossrefPubMedGoogle Scholar
  • 8 Lehnert T, Rudek B, Kienle P. et al . Impact of diagnostic laparoscopy on the management of gastric cancer: prospective study of 120 consecutive patients with primary gastric adenocarcinoma.  Br J Surg. 2002;  89 471-475
    CrossrefPubMedGoogle Scholar
  • 9 Bryan R T, Cruickshank N R, Needham S J. et al . Laparoscopic peritoneal lavage in staging gastric and oesophageal cancer.  Eur J Surg Oncol. 2001;  27 291-297
    CrossrefPubMedGoogle Scholar
  • 10 Roder J D, Bottcher K, Siewert J R. et al . Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992.  Cancer. 1993;  72 2089-2097
    PubMedGoogle Scholar
  • 11 Wilke H, Stahl M. Magenkarzinom. Schmoll HH, Höffken K, Possinger K Kompendium internistische Onkologie. Springer, 1999: 895-920
    Google Scholar
  • 12 Bonenkamp J J, Songun I, Hermans J. et al . Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients.  Lancet. 1995;  345 745-748
    CrossrefPubMedGoogle Scholar
  • 13 Cuschieri A, Weeden S, Fielding J. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.  Br J Cancer. 1999;  79 1522-1530
    CrossrefPubMedGoogle Scholar
  • 14 Wilke H, Preusser P, Fink U. et al . Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin.  J Clin Oncol. 1989;  7 1318-1326
    PubMedGoogle Scholar
  • 15 Plukker J T, Mulder N H, Sleijfer D T. et al . Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil.  Br J Surg. 1991;  78 955-958
    PubMedGoogle Scholar
  • 16 Lerner A, Gonin R, Steele G DJ. et al . Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial.  J Clin Oncol. 1992;  10 536-540
    PubMedGoogle Scholar
  • 17 Cascinu S, Labianca R, Graziano F. et al . Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).  Br J Cancer. 1998;  78 390-393
    PubMedGoogle Scholar
  • 18 Gallardo-Rincon D, Onate-Ocana L F, Calderillo-Ruiz G. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.  Ann Surg Oncol. 2000;  7 45-50
    CrossrefPubMedGoogle Scholar
  • 19 Menges M, Schmidt C, Lindemann W. et al . Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate.  J Cancer Res Clin Oncol. 2003;  129 423-429
    CrossrefPubMedGoogle Scholar
  • 20 Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomised, controlled trial (the MAGIC trial).  Proc Am Soc Clin Oncol. 2003;  22: 249; abstr. 998
    PubMedGoogle Scholar
  • 21 Hermans J, Bonenkamp J J, Boon M C. et al . Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.  J Clin Oncol. 1993;  11 1441-1447
    PubMedGoogle Scholar
  • 22 Earle C C, Maroun J A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials.  Eur J Cancer. 1999;  35 1059-1064
    PubMedGoogle Scholar
  • 23 Mari E, Floriani I, Tinazzi A. et al . Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente).  Ann Oncol. 2000;  11 837-843
    CrossrefPubMedGoogle Scholar
  • 24 Macdonald J S, Smalley S R, Benedetti J. et al . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophagel junction.  N Engl J Med. 2001;  345 725-730
    CrossrefPubMedGoogle Scholar
  • 25 Pyrhonen S, Kuitunen T, Nyandoto P. et al . Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.  Br J Cancer. 1995;  71 587-591
    CrossrefPubMedGoogle Scholar
  • 26 Glimelius B, Ekstrom K, Hoffman K. et al . Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.  Ann Oncol. 1997;  8 163-168
    CrossrefPubMedGoogle Scholar
  • 27 Wils J A, Klein H O, Wagener D J. et al . Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.  J Clin Oncol. 1991;  9 827-831
    PubMedGoogle Scholar
  • 28 Webb A, Cunningham D, Scarffe J H. et al . Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.  J Clin Oncol. 1997;  15 261-267
    PubMedGoogle Scholar
  • 29 Ajani J, van Cutsem E, Moiseyenko V. et al . Docetaxel, cisplatin, 5-fluorouracil compared to cisplatin and 5-fluorouracil for chemonaive patients with metastasic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial.  Proc Am Soc Clin Oncol. 2003;  22: 249; abstract 999
    PubMedGoogle Scholar
  • 30 Pozzo C, Bugat R Peschel C. et al . Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric of gastro-oesophageal junction adenocarcinoma: final results of a randomized phase II study.  Proc Am Soc Clin Oncol. 2001;  20 abstract 531
    PubMedGoogle Scholar
  • 31 Bouche O, Raoul J L, Giovanini M. et al . Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): Final results of study FFCD 9803.  Proc Am Soc Clin Oncol. 2003;  22 abstract 1033
    PubMedGoogle Scholar
  • 32 Louvet C, Andre T, Tigaud J M. et al . Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.  J Clin Oncol. 2002;  20 4543-4548
    CrossrefPubMedGoogle Scholar
  • 33 Sumpter K A, Harper-Wynne C, Cunningham D. et al . Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation.  Proc Am Soc Clin Oncol. 2003;  22 abstract 1031
    PubMedGoogle Scholar
  • 34 Wilke H, Korn M, Vanhofer U. et al . Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.  J Infus Chemother. 1996;  6 123-126
    PubMedGoogle Scholar
  • 35 Graziano F, Santini D, Testa E. et al . A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer.  Br J Cancer. 2003;  89 1428-1432
    CrossrefPubMedGoogle Scholar
  • 36 Kono K, Takahashi A, Amemiya H. et al . Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer.  Int J Cancer. 2002;  98 216-220
    CrossrefPubMedGoogle Scholar
  • 37 Takehana T, Kunitomo K, Kono K. et al . Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.  Int J Cancer. 2002;  98 833-837
    CrossrefPubMedGoogle Scholar
  • 38 Allgayer H, Babic R, Gruetzner K U. et al . c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.  J Clin Oncol. 2000;  18 2201-2209
    PubMedGoogle Scholar
  • 39 Hecht J R, Ajani J A, Michaeli D. A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease.  Proc Am Soc Clin Oncol. 2003;  22: 258; abstract 1035
    PubMedGoogle Scholar

PD Dr. Markus Menges

Klinik für Innere Medizin, Diakonie-Krankenhaus, Akademisches Lehrkrankenhaus der Universität Heidelberg

Diakoniestraße 10

74523 Schwäbisch Hall

Phone: 07 91/7 53-44 01

Fax: 07 91/7 53-49 10

Email: Markus.Menges@diaksha.de

      >